Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 8,207

Document Document Title
WO/2022/169921A1
The present invention is directed to compounds of formula (I) and (II), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said comp...  
WO/2022/166974A1
A pyridopyrimidinone derivative as represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt thereof or a prodrug thereof. The pyridopyrimidinone derivative has a good SOS1 inhibit...  
WO/2022/169948A1
Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and m...  
WO/2022/166642A1
A nitrogen-containing polycyclic fused ring compound represented by formula I, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. As a highly selective and effective RET inhibitor, the compound has a ...  
WO/2022/167682A1
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase, having the general Formula (I).  
WO/2022/168856A1
The present invention provides a photoelectric conversion element that has excellent manufacturing suitability and excellent photoelectric conversion efficiency with respect to light in a wide wavelength range. The present invention also...  
WO/2022/166761A1
The present invention relates to a thienopyrimidine derivative, in particular to a compound, as represented by formula I, or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containi...  
WO/2022/162107A1
The present invention relates to a crystalline form of risdiplam and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline form of risdiplam of the present inventi...  
WO/2022/165494A1
The present disclosure relates to free base and salt crystals of 2-(4-acetylbenzyl)-3-((4-fluorophenyl)amino)-5,7,7-trimethyl -7,8-dihydro-2H-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H) -one, composition comprising the same and the meth...  
WO/2022/161421A1
A biphenyl compound as shown in formula (I), a preparation method therefor and use thereof, and a pharmaceutical composition comprising the compound as an active ingredient. The compound is a novel small-molecule immunomodulator having e...  
WO/2022/163041A1
Provided are: an indole-structure-selective reaction agent and an indole-structure-selective crosslinking agent which are capable of selectively modifying, under mild conditions, an indole structure of a molecule (e.g., tryptophan) conta...  
WO/2022/156445A1
An organic compound, and an electronic component and an electronic device using same, the organic compound has a structure as shown in formula A, formula B, formula D or formula F, wherein Ar is selected from substituted or unsubstituted...  
WO/2022/159976A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2022/156803A1
Use of a pyrido[1,2-a]pyrimidone analogue. Specifically disclosed is use of a compound I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating and/or preventing cancers in the digestive tract syste...  
WO/2022/156793A1
Disclosed are a quinoxaline-based D-A-D near-infrared two-region fluorescent molecule, and a preparation method therefor and the use thereof. The quinoxaline-based D-A-D near-infrared two-region fluorescent molecule is selected from comp...  
WO/2021/257828A9
Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras su...  
WO/2022/152274A1
An FGFR inhibitor compound represented by formula (I): [formula (I)].  
WO/2022/148354A1
The present invention belongs to the technical field of medicine, and specifically relates to a polycyclic DNA-PK inhibitor compound as represented by general formula (I), a pharmaceutically acceptable salt thereof or an isomer thereof; ...  
WO/2022/148434A1
Provided are a class of pyridone multiple-membered ring derivatives and the use thereof. Specifically provided are a compound as represented by formula (VI) and a pharmaceutically acceptable salt thereof.  
WO/2022/143856A1
Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation...  
WO/2022/147302A1
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...  
WO/2022/143864A1
The compound as shown in formula (I) or a pharmaceutically acceptable salt or pharmaceutical composition thereof, and a preparation method therefor, and the use thereof as an MAT2A inhibitor. Ring A, ring Q, X, Y, X1, X2, L and R1 in for...  
WO/2022/138812A1
Provided is a tetrahydro thienopyridine sulfonamide compound that has PARG inhibition activity and is useful as an active ingredient of: a pharmaceutical composition for cancer therapy; a pharmaceutical composition for increasing the eff...  
WO/2022/135560A1
The disclosure provides novel substituted imidazo [1, 5-b] pyridazine compounds as represented in Formula I: wherein A, R 0, R 1, R 2 and R 3 are defined herein. The compounds of Formula I are kinase inhibitors, especially ATR kinase inh...  
WO/2022/134074A1
An organic electroluminescent device, a display panel, a display device and a light-emitting device are provided, belonging to the technical field of display. The organic electroluminescent device comprises an anode, an electron blocking...  
WO/2022/140661A1
The present disclosure provides therapeutic methods of treating a cancer patient with a vinca alkaloide N-oxide and an immune checkpoint inhibitor.  
WO/2022/140472A1
The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteosome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also prov...  
WO/2022/140390A1
The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to...  
WO/2022/138833A1
The present invention provides a photoelectric conversion element which is reduced in the electric field intensity dependency of a photoelectric conversion efficiency. The present invention also provides an imaging element, an optical se...  
WO/2022/140428A2
The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to...  
WO/2022/135580A1
A crystal form of a pyridopyrrole compound, and a preparation method therefor and the use thereof.  
WO/2022/136174A1
The invention relates to pharmaceutical compounds of formula (I) and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of cyclin-depen...  
WO/2022/137174A1
The present invention relates to solid forms of 7-(5-chloro-2-(3-(5-cyano-6-((1-(3,3-difluorocyclobutyl)pipe ridin-4-yl)(methyl)amino)-2-methyl-4-oxopyrido[3,4-d]pyrimid in-3(4H)-yl)prop-1-yn-1-yl)phenyl)-N-(methylsulfonyl)thieno[ 3,2-b]...  
WO/2022/127024A1
Disclosed are a nitrogen-containing heterocyclic compound and an application thereof, the nitrogen-containing heterocyclic compound having the structure shown in general formula (1) and, when used in an OLED, particularly as the main mat...  
WO/2022/133345A1
Compounds with KRAS G12C inhibitory activity are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation. Preferably the compounds fall within formula (I).  
WO/2022/127755A1
Provided herein are casein kinase inhibitors, or pharmaceutically acceptable salts thereof. Corresponding compositions, methods of treatment, and intermediates are also provided.  
WO/2022/133064A1
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions th...  
WO/2022/121825A1
A triazolo pyrazine compound, wherein the triazolo pyrazine compound is a compound as represented by formula (I) as follows, or a stereoisomer, a geometrical isomer, a tautomer, a hydrate, a solvate, and a pharmaceutically acceptable sal...  
WO/2022/125971A1
The present disclosure provides methods of treating cancer with combination therapies of a SHP2 inhibitor and a KRAS G12C inhibitor.  
WO/2022/121618A1
The present application relates to a nitrogen-containing compound, and an electronic component and electronic apparatus using same. The organic compound has a structure represented by the following formula (I). The nitrogen-containing co...  
WO/2022/118910A1
[Problem] The purpose of the present invention is to provide a compound that has a high refractive index with respect to the wavelength range of 450-750 nm in a capping layer, in order to improve the light extraction efficiency of an org...  
WO/2022/120118A1
Novel small molecule proteolysis-targeting chimeras (PROTACs) are provided, along with methods for their use as RIPK1 kinase degraders. The small molecule PROTACs described herein are useful in treating and/or preventing RIPK1 kinase-rel...  
WO/2022/117111A1
Disclosed are a salt of a pyrrolopyrimidine compound, a crystalline form thereof, and an application thereof. Specifically provided are a crystal form of the compound represented by the formula I, a salt thereof, and a hydrate of the sal...  
WO/2022/110052A1
A nitrogen-containing heterocyclic 5-HT3 receptor modulator, a preparation method therefor and use thereof, relating to the field of medicinal chemistry. The nitrogen-containing heterocyclic 5-HT3 receptor modulator is a compound as repr...  
WO/2022/113371A1
Provided is a drug used for the treatment or prevention of cerebral hemorrhage, the drug containing, as an active ingredient, the compound of formula (I), or a pharmaceutically acceptable salt, ester or solvate thereof.  
WO/2022/111636A1
The present invention relates to a fused tricyclic compound, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a fused tricyclic compound represented by general formula ...  
WO/2022/111729A1
Disclosed are a salt form used as a CDC7 inhibitor and a crystal form thereof, and specifically disclosed is a compound represented by formula (II), a crystal form thereof, a preparation method therefor, and an application thereof in the...  
WO/2022/114065A1
Provided are: a material that provides high sensitivity and high resolution to a photoelectric conversion element for imaging; and a photoelectric conversion element for imaging, using said material. This material of a photoelectric conv...  
WO/2022/109495A1
Provided herein are, inter alia, methods and compositions for linking RNA stem loops. The methods include linking a first RNA stem loop and a second RNA stem loop by way of a preQ1 linking compound.  
WO/2022/105313A1
The present application relates to an organic compound, and an organic electroluminescent device and an electronic device using the same. The structure of the organic compound is as shown in formula I. When the organic compound of the pr...  

Matches 1 - 50 out of 8,207